Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/Primary Central Nervous System Lymphoma

Rare Cancers

Primary Central Nervous System Lymphoma (PCNSL) Clinical Trials

Also called PCNSL, Primary CNS Lymphoma, Brain Lymphoma, CNS Lymphoma, Primary Intraocular Lymphoma, Vitreoretinal Lymphoma, Relapsed Refractory PCNSL

Lymphoma is a cancer of lymphocytes, the white blood cells of the immune system. Most lymphomas start in lymph nodes.

In plain words, primary CNS lymphoma is a fast-growing cancer of immune cells that starts in the brain, spinal cord or eyes. It usually stays there and can cause headaches, confusion, limb weakness or vision changes.

Get an email when new Primary Central Nervous System Lymphoma trials open or the FDA decides. Get alerts

Primary Central Nervous System Lymphoma

Where treatments stand, from ClinicalTrials.gov and FDA labels

FDA review1

Tirabrutinib, Dec 18, 2026

FDA-approved medicines0

No medicine's current FDA label names Primary Central Nervous System Lymphoma yet.

Primary Central Nervous System Lymphoma has no FDA-approved medicines, 70 open or active clinical trials, and a pending FDA decision on Tirabrutinib, due Dec 18, 2026.

Labels checked October 21, 2026.Download the data

Latest for Primary Central Nervous System Lymphoma

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about Primary Central Nervous System Lymphoma

Primary CNS lymphoma starts inside the central nervous system instead, in the brain, the spinal cord, the meninges that wrap them, or the eye, and in almost all cases it stays confined there. Under the microscope nearly every PCNSL is a diffuse large B-cell lymphoma, and they often carry changes in 2 genes, MYD88 and CD79B, that keep a growth signal called the B-cell receptor pathway switched on. That pathway runs through an enzyme called BTK, which is why BTK-blocking drugs are being tested.

Keep reading about Primary Central Nervous System Lymphoma

Diagnosis usually starts with an MRI, then a needle biopsy of the tumor guided by a frame or computer, because surgery to remove the tumor does not help and is not used. An eye exam with dilated pupils and a spinal tap are part of the workup, since the eyes and spinal fluid can be involved without causing obvious symptoms. There is no formal staging system.

PCNSL is aggressive but treatable. In published trials the median survival ranges from 2 to 5 years, and outcomes are best in people under 60 who are well enough to carry out most daily activities and do not have a weakened immune system. The disease comes back often: roughly 20-30% of patients do not respond to the first treatment and up to 60% eventually relapse, which is where most of the new drug research is focused.

What are the symptoms of Primary Central Nervous System Lymphoma?

These are common symptoms of Primary Central Nervous System Lymphoma, and how strong they are varies from person to person.

  • Headaches, nausea or vomiting
  • Confusion
  • Weakness in an arm or leg
  • Seizures
  • Double vision, since the eyes are part of the central nervous system
  • Hearing loss

Who gets Primary Central Nervous System Lymphoma?

PCNSL is mostly a disease of older adults, with more than half of patients diagnosed at 60 or older. A weakened immune system raises the risk sharply: people with HIV, people who have had an organ transplant, and people on long-term immune-suppressing medicines are all more likely to develop it, and in those cases the lymphoma is almost always linked to the Epstein-Barr virus. It also develops in people with no known risk factor at all.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Which new Primary Central Nervous System Lymphoma medicines are in trials?

Investigational medicines Trial Friend tracks for Primary Central Nervous System Lymphoma, with trial results, safety findings and where each one stands.

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for Primary Central Nervous System Lymphoma

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted Primary Central Nervous System Lymphoma resources

Reputable organizations and medical references for learning more about Primary Central Nervous System Lymphoma, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for Primary Central Nervous System Lymphoma

Use this Primary Central Nervous System Lymphoma clinical trial finder to see the 19 studies recruiting patients and 1 not yet recruiting in the United States and worldwide, with eligibility criteria in plain English. Of these, 17 test a treatment and 3 are observational studies or registries; each card says which. Every trial comes from ClinicalTrials.gov.

FDA decision ahead: Tirabrutinib, due December 18, 2026. All upcoming decisions

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

70 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Recently updatedNCT07104032

IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

Intervention: Tirabrutinib, Rituximab, Temozolomide

Sponsor: Ono Pharmaceutical Co., Ltd. · Deciphera Pharmaceuticals, LLC

The purpose of this clinical trial is to evaluate efficacy and safety of tirabrutinib alone compared with rituximab and temozolomide (R-TMZ) combination therapy in participants with Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL).

Ages 18 Years+
Started Jun 2026Updated yesterdayEst. Dec 2027 (~1y 1m)
RecruitingTreatment trialRecently updatedNCT07710131

Neurocognitive Assessment CNSL and LGG

Intervention: Digital Cognitive Assessment (TestMyBrain and Mobile Toolbox), Traditional Neuropsychological Testing, Quality of Life and Mood Questionnaires, Brain MRI (Standard of Care)

Sponsor: Dana-Farber Cancer Institute

This study is to determine whether self-administered digital cognitive tests can serve as accurate and reliable alternatives to established neuropsychological tests for evaluating cognitive functioning in participants with primary central nervous system lymphoma and low-grade gliomas.

Ages 18 Years+1 location
Started Sep 2026Updated yesterdayEst. Jan 2028 (~1y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT03375619

Long-term Follow-up Study of Patients Receiving CAR-T Cells

Intervention: Long-Term Follow-Up of Participants who Received CAR-T cells

Sponsor: Medical College of Wisconsin

This protocol is designed as a long-term follow-up study of participants who will receive CAR-T cells as part of a clinical trial at the Medical College of Wisconsin/ Froedtert Hospital. The clinical trials include the following:

Ages 18 Years to 80 Years1 location
Started Dec 2017Updated 4 days agoEst. Jan 2035 (~8y 1m)
RecruitingObservational study, no treatment givenRecently updatedNCT05011045

Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies

Intervention: Magnetic Resonance Imaging, Neurocognitive Assessment, Quality-of-Life Assessment, Questionnaire Administration

Sponsor: M.D. Anderson Cancer Center

This study assesses neurocognitive outcomes after receiving radiation therapy to the brain (whole brain radiation therapy) in patients with blood cancers (hematologic malignancies). This may help researchers learn more about the effects of whole brain radiation therapy on memory ...

Ages 18 Years+1 location
Started Jan 2020Updated 5 days agoEst. Oct 2028 (~1y 11m)
RecruitingTreatment trialPhase 1Recently updatedNCT06922604

Glofitamab With Obinutuzumab Pre-treatment for the Treatment of Central Nervous System Lymphoma

Intervention: Biospecimen Collection, Computed Tomography, Glofitamab, Lumbar Puncture, Magnetic Resonance Imaging, Obinutuzumab, Positron Emission Tomography

Sponsor: City of Hope Medical Center

This phase Ib trial tests the safety and side effects of glofitamab after pre-treatment with obinutuzumab and how well they work in treating patients with central nervous system (CNS) lymphoma. Glofitamab is a bispecific antibody that can bind to two different antigens (substance...

Ages 18 Years+1 location
Started Jul 2025Updated 2 weeks agoEst. Jan 2029 (~2y 1m)
Find Primary Central Nervous System Lymphoma trials near you, ranked by distance →
Active trial locations62 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+54 more

Trial Pipeline

Jan 2021 to Nov 2031
2021
2023
2025
2027
2029
2031
now
Phase 1
Phase 2
Phase 3
Observational
Observational
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about Primary Central Nervous System Lymphoma trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run a Primary Central Nervous System Lymphoma foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

Primary Central Nervous System Lymphoma patient communities

Facebook groups, Reddit communities and YouTube channels where Primary Central Nervous System Lymphoma patients, caregivers and advocacy groups talk.

Companies developing Primary Central Nervous System Lymphoma treatments

Drugmakers that list Primary Central Nervous System Lymphoma in their rare disease portfolio, with makers of its treatments first.

Questions people ask about Primary Central Nervous System Lymphoma